Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Xspray Pharma AB ( (SE:XSPRAY) ) has shared an update.
Xspray Pharma AB has announced a one-day delay in the trading of subscription rights and paid subscribed shares (BTAs) related to its ongoing rights issue, now set to begin on August 27, 2025. This adjustment in the timetable is part of the company’s strategic financial maneuvers to strengthen its market position and support its ambitious product development goals, potentially impacting stakeholders and investors interested in the company’s growth trajectory.
More about Xspray Pharma AB
Xspray Pharma AB is a pharmaceutical company focused on developing improved versions of marketed protein kinase inhibitors (PKIs) using its patented HyNap™ technology platform. The company aims to lead the market in enhanced PKIs for cancer treatment, with its lead drug candidate, Dasynoc®, currently under FDA review. Xspray Pharma is expanding its product portfolio with optimized versions of existing cancer drugs.
Average Trading Volume: 40,209
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.64B
Learn more about XSPRAY stock on TipRanks’ Stock Analysis page.